These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26133779)

  • 1. Correction: Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study.
    Clin Cancer Res; 2015 Jul; 21(13):3096. PubMed ID: 26133779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.
    Shariat SF; Karakiewicz PI; Godoy G; Karam JA; Ashfaq R; Fradet Y; Isbarn H; Montorsi F; Jeldres C; Bastian PJ; Nielsen ME; Müller SC; Sagalowsky AI; Lotan Y
    Clin Cancer Res; 2009 Nov; 15(22):7012-9. PubMed ID: 19903782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells.
    Clin Cancer Res; 2015 Jul; 21(13):3095. PubMed ID: 26133778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing National Institutes of Health funding of emergency medicine to four medical specialties.
    Bessman SC; Agada NO; Ding R; Chiang W; Bernstein SL; McCarthy ML
    Acad Emerg Med; 2011 Sep; 18(9):1001-4. PubMed ID: 21854480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.
    Fristrup N; Ulhøi BP; Birkenkamp-Demtröder K; Mansilla F; Sanchez-Carbayo M; Segersten U; Malmström PU; Hartmann A; Palou J; Alvarez-Múgica M; Zieger K; Borre M; Ørntoft TF; Dyrskjøt L
    Am J Pathol; 2012 May; 180(5):1824-34. PubMed ID: 22449953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology?
    Krabbe LM; Lotan Y; Bagrodia A; Gayed BA; Darwish OM; Youssef RF; Bolenz C; Sagalowsky AI; Raj GV; Shariat SF; Kapur P; Margulis V
    J Urol; 2014 Apr; 191(4):926-31. PubMed ID: 24060642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.
    Kamat AM; Dinney CP; Gee JR; Grossman HB; Siefker-Radtke AO; Tamboli P; Detry MA; Robinson TL; Pisters LL
    Cancer; 2007 Jul; 110(1):62-7. PubMed ID: 17542024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.
    Tang J; Deng R; Luo RZ; Shen GP; Cai MY; Du ZM; Jiang S; Yang MT; Fu JH; Zhu XF
    Breast Cancer Res Treat; 2016 Apr; 156(2):403-4. PubMed ID: 26960710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: identification of predictive features using bootstrap method.
    Kapur U; Antic T; Venkataraman G; Durazo-Arvizu R; Quek MM; Flanigan RC; Wojcik EM
    Urology; 2007 Nov; 70(5):1028-33. PubMed ID: 18068480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2019 Jul; 176(1):251. PubMed ID: 30982934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
    Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
    Weiss C; von Römer F; Capalbo G; Ott OJ; Wittlinger M; Krause SF; Sauer R; Rödel C; Rödel F
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1455-60. PubMed ID: 19231102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
    Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
    J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of new AJCC exclusion criteria for subepithelial prostatic stromal invasion from pT4a bladder urothelial carcinoma.
    Patel AR; Cohn JA; Abd El Latif A; Miocinovic R; Steinberg GD; Paner GP; Hansel DE
    J Urol; 2013 Jan; 189(1):53-8. PubMed ID: 23164389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining.
    Skagias L; Politi E; Karameris A; Sambaziotis D; Archondakis A; Ntinis A; Moreas I; Vasou O; Koutselini H; Patsouris E
    Anticancer Res; 2009 Oct; 29(10):4163-7. PubMed ID: 19846967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
    Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.